Medicines

Home / Our therapy areas / Medicines

We cannot provide detailed information about our prescription medicines on this website, in compliance with regulations.

Our medicines are approved in individual countries for specific uses and the information we provide for patients is governed by local regulations. In some cases, health care professionals and patients can visit local AstraZeneca websites to find out more about our medicines. Please note that in some countries we are not allowed to provide very much, or sometimes any, information on our prescription medicines so you should seek alternative trustworthy sources. Always ask a healthcare professional for advice about medicines.



Reporting of side effects

The safety of our patients is very important to us. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet.

By reporting any side effects that you may experience, you are helping to provide more information on the safety of our medicines. Report a possible side-effect to AstraZeneca by 'report side-effect' below. If you are based in the UK, you can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.



Oncology

Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.


Calquence

acalabrutinib

Enhertu

trastuzumab deruxtecan

Faslodex

fulvestrant

Imfinzi

durvalumab

Iressa

gefitinib

Koselugo

selumetinib

Lumoxiti

moxetumomab pasudotox-tdfk

Lynparza

olaparib

Orpathys

savolitinib

Tagrisso

osimertinib

Zoladex

goserelin acetate implant

Cardiovascular, Renal & Metabolism

Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.


Andexxa/Ondexxya

Coagulation Factor Xa (Recombiant), Inactivated-zhzo

Atacand, Atacand HCT, Atacand Plus

candesartan cilexetil

Brilinta/Brilique

ticagrelor

Bydureon

exenatide

Byetta

exenatide injection

Crestor

rosuvastatin

Farxiga/Forxiga

dapagliflozin

Komboglyze

saxagliptin and metformin HCl

Kombiglyze XR

saxagliptin and metformin XR

Lokelma

Sodium zirconium cyclosilicate

Onglyza

saxagliptin

Plendil, Modip, Splendil, Munobal, Flodil 

felodipine

Qtern

dapagliflozin and saxagliptin

Seloken ZOK, Toprol-XL, Betaloc ZOK

metoprolol succinate

Symlin

pramlintide acetate

Tenormin, Tenormine, Prenormine, Atenol 

atenolol

XIGDUO

dapagliflozin and metformin HCI

XIGDUO XR 

dapagliflozin and metformin HCI extended-release

Zestril

lisinopril dihydrate

Respiratory & Immunology

Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.


Accolate, Accoleit, Vanticon

zafirlukast

Bevespi Aerosphere

glycopyrronium/formoterol fumarate

Breztri Aerosphere

budesonide/glycopyrronium/formoterol fumarate

Bricanyl Respules

terbutaline

Bricanyl Turbuhaler

terbutaline in a dry powder inhaler

Daliresp/Daxas

roflumilast

Duaklir Genuair

aclidinium/formoterol

Eklira Genuair/Tudorza/Bretaris

aclidinium, a LAMA

Fasenra

benralizumab

Oxis Turbuhaler

Oxis Turbuhaler

Pulmicort Respules

budesonide inhalation suspension

Pulmicort Turbuhaler

budesonide

Rhinocort

budesonide

Saphnelo

anifrolumab

Symbicort pMDI

budesonide/formoterol

Symbicort Turbuhaler

budesonide/formoterol

Tezspire

tezepelumab

Vaccines and Immune Therapies

Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.

Evusheld

tixagevimab and cilgavimab

Fluenz Tetra/FluMist Quadrivalent

influenza vaccine live, intra-nasal

Synagis 

palivizumab

Rare Disease

Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.


Kanuma

sebelipase alfa

Koselugo

selumetinib

Soliris

eculizumab

Strensiq

asfotase alfa

Ultomiris

ravulizumab

Voydeya

danicopan


Early access to AstraZeneca investigational medicinal products

We recognise that there are circumstances where patients with serious or life-threatening diseases have exhausted all available therapeutic options and may not be eligible to enrol in one of our clinical trials. In such circumstances individual patients may be eligible for early access to an AstraZeneca investigational medicinal product.

 


Veeva ID: Z4-51513
Date of preparation: December 2022